Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 12 years of age or older in good general health~* Investigator's Static Global Assessment (ISGA) score of 2 or greater at Baseline~Exclusion Criteria:~* Any nodulo-cystic lesions at Baseline~* Pregnancy or breast feeding~* History or presence of regional enteritis or inflammatory bowel disease or similar symptoms.~* Treatment with estrogens, including oral, implanted and topical contraceptives, androgens, or anti-androgenic agents for 12 weeks or less prior to study start.~* Use of topical anti-acne medications within the past 2 weeks.~* Use of topical or systemic antibiotics on the face within the past 2 weeks.~* Use of topical or systemic corticosteroids within the past 2 weeks.~* Use of systemic retinoids within the past 3 months.~* Use of astringents, toners and skin cleansers for less than 2 weeks prior to the start of the study.~* Concomitant use of facial product containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or α- or β-hydroxy acids.~* Concomitant use of mega-doses of certain vitamins, such as vitamin D (\>2000IU QD) vitamin B12, haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.~* Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2 weeks or during the study.~* Concomitant use of tanning booths or sunbathing.~* Known hypersensitivity or previous allergic reaction to any of the active components, lincomycin, retinoids or excipients of the study product~* A significant medical history of or are currently immunocompromised~* Current drug or alcohol abuse. (Drug screening not required.)~* Use of any investigational therapy within 4 weeks of enrollment.~* Any other condition which, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CT Gel
- 2 (Type: ACTIVE_COMPARATOR): Clindamycin Gel (clindamycin)
- 3 (Type: ACTIVE_COMPARATOR): Tretinoin Gel (tretinoin)
- 4 (Type: PLACEBO_COMPARATOR): Vehicle Gel

Based on this trial design, predict the completion outcome and termination type (if applicable).